EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review

Myriam Marfil-Cantón, Alvaro Prados-Carmona, Marta Cebolla-Verdugo, Husein Husein-ElAhmed, Fernando Campos iD, Ricardo Ruiz-Villaverde iD

Journal of Clinical Medicine · 17.11.2024 · 13 (22) · 6925

DOI: 10.3390/jcm13226925 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.11.2024. Verfasst von Myriam Marfil-Cantón und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atopic dermatitis (AD) is the most prevalent inflammatory dermatological disorder, affecting a significant percentage of the global population. This chronic disease has a multifactorial and intricate pathogenesis, influenced by genetic predisposition, skin barrier dysfunction, immune dysregulation, neuroimmune mechanisms, and alterations in the skin microbiome, among other factors.

Methods

The treatment of AD has faced significant clinical challenges due to the ineffectiveness of conventional therapies. However, recent advances in understanding its pathophysiology have led to the introduction of new therapeutic options. Recently, the OX40 receptor has been identified as a key factor in the development of AD. Recent studies have demonstrated that blocking the OX40 ligand with monoclonal antibodies significantly and sustainably improves the signs and symptoms of moderate to severe AD.

Results

A comprehensive review of the available literature on anti-OX40 treatments in atopic dermatitis that evaluates their mechanism of action, their clinical efficacy, and the prospects of this promising therapeutic option for improving AD management is provided.

Conclusions

Anti-OX40 and anti-OX40L blockers are a promising therapeutic alternative for the management of moderate–severe atopic dermatitis. Prospective analytical studies are needed to determine whether this new therapeutic target represents a qualitative advance in modifying the progression of the disease.

Schlagwörter

Stichwörter der Autor:innen

OX40OX40Latopic dermatitisbiological therapyinflammationmonoclonal antibody

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain.
  • Instituto Biosanitario de Granada, Ibs, 18012 Granada, Spain.
  • Dermatology Department, Hospital Universitario de Baza, 18800 Granada, Spain.
  • Tissue Engineering Group, Department of Hisotology, University of Granada, 18016 Granada, Spain.

ORCID-Profile: Fernando Campos, Ricardo Ruiz-Villaverde

Zitieren

APA

Marfil-Cantón, M., Prados-Carmona, A., Cebolla-Verdugo, M., Husein-ElAhmed, H., Campos, F., & Ruiz-Villaverde, R. (2024). Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review. Journal of Clinical Medicine, 13(22), 6925. https://doi.org/10.3390/jcm13226925

Vancouver

Marfil-Cantón M, Prados-Carmona A, Cebolla-Verdugo M, Husein-ElAhmed H, Campos F, Ruiz-Villaverde R. Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review. Journal of Clinical Medicine. 2024;13(22):6925. doi:10.3390/jcm13226925

BibTeX
@article{MarfilCantn2024,
  author = {Marfil-Cantón, Myriam and Prados-Carmona, Alvaro and Cebolla-Verdugo, Marta and Husein-ElAhmed, Husein and Campos, Fernando and Ruiz-Villaverde, Ricardo},
  title = {Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {22},
  pages = {6925},
  doi = {10.3390/jcm13226925}
}
Kostenlos starten →